Literature DB >> 1651156

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

Y Kawato1, M Aonuma, Y Hirota, H Kuga, K Sato.   

Abstract

It is known that 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11), a semisynthesized derivative of camptothecin (CPT), has a potent antitumor activity in vivo, but 7-ethyl-10-hydroxycamptothecin (SN-38), a metabolite of CPT-11, shows much stronger cytotoxicity in vitro than CPT-11. In this study, we demonstrated that the relaxation of SV40 DNA plasmids by type I DNA topoisomerase prepared from P388 murine leukemia cells was inhibited by 50% by SN-38 at approximately 1 microM, although CPT-11 at 1 mM slightly inhibited the relaxation. SN-38 and CPT showed strong, time-dependent inhibitory activity against DNA synthesis of P388 cells. However, CPT-11 weakly inhibited DNA synthesis independently of time with coincident inhibition of the total thymidine uptake by the cells. By alkaline and neutral elution assays, it was demonstrated that SN-38 caused much more frequent DNA single-strand breaks in P388 cells than did CPT-11. The same content of SN-38 and a similar frequency of single-strand breaks were detected in the cells treated with SN-38 at 0.1 microM or with CPT-11 at 100 microM. Therefore, single-strand breaks by CPT-11 seem to be due to SN-38 produced from CPT-11 in cells. These results indicate that CPT-11 itself possesses a marginal antiproliferative effect but that SN-38 plays an essential role in the mechanism of action of CPT-11.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1651156

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  193 in total

1.  Identification of genes highly expressed in G2-arrested Chinese hamster ovary cells by differential display analysis.

Authors:  Y Sasaki; F Itoh; H Suzuki; T Kobayashi; H Kakiuchi; M Hareyama; K Imai
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

3.  3D superhydrophobic electrospun meshes as reinforcement materials for sustained local drug delivery against colorectal cancer cells.

Authors:  Stefan T Yohe; Victoria L M Herrera; Yolonda L Colson; Mark W Grinstaff
Journal:  J Control Release       Date:  2012-06-06       Impact factor: 9.776

Review 4.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

Review 5.  The emerging role of antibody-drug conjugates in urothelial carcinoma.

Authors:  Michael Lattanzi; Jonathan E Rosenberg
Journal:  Expert Rev Anticancer Ther       Date:  2020-07-21       Impact factor: 4.512

6.  Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer.

Authors:  Cleo E Rolle; Rajani Kanteti; Mosmi Surati; Suvobroto Nandi; Immanuel Dhanasingh; Soheil Yala; Maria Tretiakova; Qudsia Arif; Todd Hembrough; Toni M Brand; Deric L Wheeler; Aliya N Husain; Everett E Vokes; Ajit Bharti; Ravi Salgia
Journal:  Mol Cancer Ther       Date:  2013-12-10       Impact factor: 6.261

7.  Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.

Authors:  Eric Lévesque; Anne-Sophie Bélanger; Mario Harvey; Félix Couture; Derek Jonker; Federico Innocenti; Erica Cecchin; Giuseppe Toffoli; Chantal Guillemette
Journal:  J Pharmacol Exp Ther       Date:  2013-02-05       Impact factor: 4.030

8.  Alteration of Drug Sensitivity in Human Colon Cancer Cells after Exposure to Heat: Implications for Liver Metastasis Therapy using RFA and Chemotherapy.

Authors:  Ryouji Makizumi; Weng-Lang Yang; Randall P Owen; Rohit R Sharma; T S Ravikumar
Journal:  Int J Clin Exp Med       Date:  2008-02-28

9.  Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

Authors:  Shuko Hakata; Jun Terashima; Yu Shimoyama; Kouji Okada; Shiho Fujioka; Erika Ito; Wataru Habano; Shogo Ozawa
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

Review 10.  Topoisomerase inhibitors. A review of their therapeutic potential in cancer.

Authors:  B K Sinha
Journal:  Drugs       Date:  1995-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.